Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units
Cosmos Health announced an exclusive distribution agreement with Pharmalink to market its Sky Premium Life nutraceuticals in the UAE. Pharmalink, a leading UAE healthcare organization, will manage sales, marketing, logistics, and distribution functions. Cosmos has received an initial order of 130,000 units and forecasts sales of over 500,000 units in the first year and more than 3 million units over the next five years. Pharmalink's CEO, Dr. Abdul Rauf Jabour, and Cosmos Health's CEO, Greg Siokas, expressed optimism about the partnership's potential to penetrate the UAE nutritional supplements market.
- Cosmos Health secures an initial purchase order of 130,000 units.
- Forecasted sales of over 500,000 units in the first year.
- Projection of more than 3 million units ordered over the next five years.
- Partnership with Pharmalink, a major player in the UAE healthcare market with extensive distribution capabilities.
- None.
Insights
The exclusive distribution agreement between Cosmos Health and Pharmalink marks a significant step for Cosmos, especially given the UAE's lucrative market for nutritional supplements. Pharmalink’s extensive network of 3,000 pharmacies and its established presence provides a strong foundation for penetrating the UAE market. The initial purchase order of 130,000 units is a good starting point, but what’s more impressive is the projection of orders exceeding 3 million units over the next five years.
Short-term, this partnership promises an immediate revenue inflow for Cosmos Health and a positive impact on their sales figures. On the long-term, establishing a stronghold in the UAE market could lead to sustained revenue growth and enhanced brand recognition in the Middle East.
For investors, understanding the market dynamics of the UAE is crucial. The country’s high disposable income and growing health consciousness are driving demand for premium health products. Cosmos Health's Sky Premium Life range is positioned well to cater to this demand. However, investors should also be aware of the competition landscape, as other global nutraceutical brands are likely eyeing the same market.
Additionally, regulatory compliance in the UAE is a key factor. Pharmalink’s role in handling regulatory affairs should mitigate potential hurdles, ensuring a smoother market entry and expansion for Cosmos Health.
The agreement with Pharmalink and the initial purchase order is a positive signal for Cosmos Health's financial health. The UAE market is one of the wealthiest and most health-conscious regions globally, which bodes well for the profitability of Sky Premium Life products.
Revenue Projections: The anticipated order volume of over 500,000 units in the first year and 3 million units over the next five years suggests a significant boost to Cosmos Health's topline. If we assume a conservative average selling price of
Furthermore, Pharmalink’s established distribution network reduces operational risks and associated costs, potentially improving Cosmos's profit margins. However, investors should also consider the working capital requirements and the cost of scaling production to meet demand.
Financial Stability: Given the stable economic conditions in the UAE and Pharmalink’s market position, the revenue streams are likely to be reliable. Nonetheless, monitoring the payment cycles and any geopolitical developments in the region can help investors gauge the deal’s long-term stability.
CHICAGO, IL / ACCESSWIRE / June 27, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has signed an exclusive distribution agreement (the "Agreement") with Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE).
As part of the Agreement, Pharmalink will be responsible for all key functions, including sales and marketing, regulatory affairs, logistics, supply, and distribution of Sky Premium Life products in the UAE. Cosmos Health has secured its first purchase order from Pharmalink for 130,000 units and anticipates receiving orders of more than 500,000 units in the first year and in excess of 3,000,000 units over the next five years.
Pharmalink, led by CEO Dr. Abdul Rauf Jabour, is one of the largest healthcare organizations in the UAE. With over 30 years of experience, a workforce of 1,400 employees, a network of 120 partners, a portfolio of 430 brands, and access to over 3,000 pharmacies, including its own MEDICINA chain of about 200 operational pharmacies, we believe that Pharmalink is well positioned to help Cosmos Health effectively gain market share in the lucrative UAE nutritional supplements market.
Left: Pharmalink's CEO, Dr. Abdul Rauf Jabour, signing the Agreement at Pharmalink's facilities in Dubai
Right: Pharmalink's CEO, Dr. Abdul Rauf Jabour with Cosmos Health's CEO, Greg Siokas.
Dr. Abdul Rauf Jabour, CEO of Pharmalink, stated: "We are extremely excited to partner with Cosmos Health, and particularly with Greg Siokas, to bring Sky Premium Life products to the UAE market. We believe this will be the starting point for a very successful, long-lasting relationship."
Greg Siokas, CEO of Cosmos Health, stated: "We are thrilled to announce our agreement with Pharmalink. This partnership will enable us to launch our Sky Premium Life products dynamically in the UAE, especially in affluent markets such as Dubai and Abu Dhabi. We project receiving purchase orders exceeding 3 million units over the next five years and look forward to expanding our collaboration with Pharmalink."
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on accesswire.com
FAQ
What is the recent partnership Cosmos Health announced?
What is the initial purchase order Cosmos Health received from Pharmalink?
How many units does Cosmos Health project to sell in the first year in the UAE?
What is the long-term sales projection for Cosmos Health’s Sky Premium Life products in the UAE?
Who is managing the distribution of Cosmos Health products in the UAE?
What is the significance of Cosmos Health's agreement with Pharmalink for investors?
